Warfarin - How Good Are we at Maintaining Target Range ?
Completed
- Conditions
- Atrial Fibrillation
- Registration Number
- NCT01081327
- Lead Sponsor
- University of Dundee
- Brief Summary
Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5000
Inclusion Criteria
- Prescription for Warfarin
- Atrial Fibrillation
Exclusion Criteria
- Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma.
- Conditions with increased risk of bleeding.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bleeding Complication 10 years Any bleeding event requiring hospitalisation and / or blood transfusion. Any death attributable to bleeding i.e. Intracerebral bleed.
Cardiovascular outcome 10 years Ischaemic event e.g. Cerebral infarction / Myocardial infarction / death attributed to ischaemic event
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre for Cardiovascular and Lung Biology, Univeristy of Dundee
🇬🇧Dundee, United Kingdom